This is a study to see if a new medicine called icovamenib can help people with Type 2 Diabetes (T2D) reach their blood sugar goals. **Type 2 Diabetes** is when the body can't use sugar properly and blood sugar levels get too high. **HbA1c** is a blood test that shows average blood sugar levels over 3 months. People in this study will continue their usual diabetes medicines plus icovamenib for one year.

• The study lasts 52 weeks (about 1 year).
• Participants must visit the doctor for ongoing check-ups.
• There may be compensation for time and travel.

Eligible participants are adults aged 18-70 with T2D, on stable diabetes medication for at least 3 months, and have HbA1c of 7.5% to 10.5%. They must also not have certain other health issues, like Type 1 Diabetes or certain liver problems. Women must have a negative pregnancy test. If you join, you'll get either icovamenib or a placebo (a pill with no medicine) and continue your regular diabetes treatment.